Masimo earnings in focus as Danaher deal nears close

Masimo is expected to report Q1 EPS of $1.43 on revenue of $398.65 million, up 5.2% and 7.2% year over year, but revenue is projected to decline sequentially from $412.5 million. The stock is trading at $178.64 versus Danaher’s $180 cash offer, with all eight analysts rating it Hold and a consensus target of $180.00. The article is chiefly about the pending $9.9 billion Danaher acquisition and how this will likely be Masimo’s final earnings report as a public company.

Analysis

The key economic point is that MASI is no longer a standalone fundamentals story; it is a short-duration event-driven instrument with a de facto floor near the deal price, but not a risk-free one. The tiny spread to consideration suggests the market is pricing in high closing probability, yet that also means the remaining upside from here is largely a function of deal certainty rather than operating beats. In other words, the earnings release matters less for valuation than for whether it changes the probability-weighted timeline to cash.

The second-order issue is that the company’s final quarters as a public entity can create avoidable slippage: merger-related costs, employee retention issues, and customer deferment if hospital buyers think product support or pricing will change post-close. That matters more for Danaher than for MASI holders, because any deterioration in the core monitoring franchise would mainly show up as a lower-than-modeled EBITDA bridge and a slower integration ramp inside DHR’s Diagnostics segment. For DHR, the market is likely underappreciating the optionality from buying a niche asset at a time when healthcare capex is still being rationed; if MASI’s monitoring installed base remains sticky, the deal can be accretive earlier than consensus assumes.

The contrarian view is that the spread may be too tight relative to the remaining regulatory and timing uncertainty. A cash deal with a long-dated close still embeds headline risk from antitrust/process delays, and the market is currently treating that as near-zero. If the print includes any hint of elevated restructuring expense or weak near-term operating trends, the stock can cheapen on a “one less reason to own it” basis, even if the deal stays intact, because there is no standalone multiple support left.

For DHR, the larger opportunity may be post-close rather than into the announcement: if management reframes the asset as an earnings-quality enhancer within Diagnostics, the stock can re-rate on synergy credibility. The real risk is not deal failure but overpaying for a lower-growth asset if integration takes longer than promised, which would cap multiple expansion and keep DHR in the penalty box versus higher-quality med-tech peers.

Key Decisions for Investors

• Maintain a small long MASI position only as a spread capture trade; keep sizing modest and treat it as a binary event-driven hold until close, with downside limited by deal price but not eliminated by regulatory/timing risk.
• For arb accounts, harvest gains into strength above the low-$179s rather than waiting for perfect execution; the remaining spread is too narrow to justify meaningful mark-to-market risk unless the close date materially shortens.
• Initiate a DHR starter long on any post-earnings weakness in the first 1-3 trading days, targeting a 6-12 month horizon; thesis is that the market is underpricing integration optionality and diagnostics mix uplift from the acquired asset.
• If MASI trades below $177 on any delay headline, consider a tactical long against cash or against DHR via a merger-spread pair; risk/reward improves sharply because the market is likely overshooting the probability of failure.
• Avoid buying MASI for operating alpha; the asymmetric trade is now event timing, not fundamentals, and the stock’s best-case upside is capped while downside from a process stumble can still be several points.